5-Amino-1MQ: Inhibiting NNMT to Prevent Fat Storage and Boost Cellular NAD+

The NNMT Problem You've Never Heard Of

In the complex ecosystem of metabolic enzymes, NNMT (Nicotinamide N-Methyltransferase) is one of the least discussed but most metabolically consequential. It does two problematic things simultaneously:

It degrades NAD+ precursors: NNMT methylates nicotinamide (NAM) — a key NAD+ precursor — converting it to 1-methylnicotinamide for excretion. Higher NNMT activity means less NAM available for NAD+ synthesis. This is why NMN supplementation alone is insufficient if NNMT activity is high — you are filling a leaky bucket.

It promotes fat cell formation: NNMT is highly expressed in adipose tissue and plays a key regulatory role in adipocyte differentiation (adipogenesis). High NNMT activity maintains an epigenetic landscape that promotes fat cell formation and sustains the obesity phenotype. Obese individuals have significantly higher adipose NNMT expression than lean individuals. ^[]

5-Amino-1MQ inhibits NNMT — addressing both problems simultaneously.

The Mouse Data

A 2019 Nature Communications study by Neelakantan et al. treated diet-induced obese mice with 5-Amino-1MQ. ^[] Results:

• Significant reduction in body weight and fat mass compared to vehicle-treated controls
• No reduction in food intake — weight loss was not due to appetite suppression
• Increased metabolic rate — indirect calorimetry showed higher oxygen consumption
• Improved insulin sensitivity and glucose tolerance
• Reduced adipocyte size — existing fat cells shrank

The finding that fat loss occurred without appetite reduction is mechanistically important: it demonstrates a passive metabolic shift — the body burns more fat as fuel without the animal eating less. This is the desirable fat loss mechanism: preserve lean mass, preferentially mobilise fat, without the neurological side effects of appetite suppressants.

The Dual NAD+ Mechanism

The combination of 5-Amino-1MQ + NMN creates a comprehensive NAD+ restoration strategy:

5-Amino-1MQ (reduce NAD+ degradation):

• Inhibit NNMT → spare nicotinamide → more substrate for NAD+ synthesis
• Less methyl group consumption from NAM methylation → preserve SAM for other methylation reactions

NMN (increase NAD+ synthesis):

• Directly provide NAD+ precursor that bypasses NAMPT rate-limiting step
• Elevate whole-body NAD+ levels independently of salvage pathway efficiency

The combination is analogous to simultaneously plugging a drain and increasing inflow. Single intervention alone is less effective than addressing both sides of the NAD+ balance.

The NNMT-Cancer Complexity

NNMT is overexpressed in multiple cancers — lung, colorectal, gastric, thyroid. In the tumour microenvironment, NNMT promotes immunosuppression and may facilitate tumour growth and metastasis. This would suggest that inhibiting NNMT could actually be beneficial in cancer contexts.

However, the biology is complex and context-dependent. In some cancer types, NNMT inhibition may have unpredictable effects on tumour biology. Given this complexity and the absence of human safety data, individuals with any cancer history should avoid 5-Amino-1MQ until substantially more evidence exists.

Practical Protocol

• Dose: 50–100mg twice daily (morning and midday) with food
• Avoid evening dosing — potential stimulatory effects from metabolic upregulation
• Cycle: 8 weeks on, 4 weeks off
• Stack: NMN 500mg + 5-Amino-1MQ 100mg in the morning for comprehensive NAD+ optimization
• Monitor: Lipid panel and liver enzymes at baseline and 8 weeks (NNMT is highly expressed in liver)